03/04/2026
🌟 Discover Semaglutide: A Game-Changer for Type 2 Diabetes Management at Diiaplus Clinic! 🌟
Are you struggling with Type 2 Diabetes? Semaglutide, available as Ozempic (injectable) or Rybelsus (oral tablet), is now approved and widely accessible in India, including generics post-patent expiry in March 2026. This GLP-1 receptor agonist helps lower blood sugar (HbA1c by up to 2.8%), promotes weight loss, and offers heart and kidney protection—ideal for Indian patients facing high diabetes burden.
Key Benefits:
✅ Improves glycemic control when diet/exercise aren't enough
✅ Supports sustainable weight management without typical weight gain from other therapies
✅ Once-weekly injection or daily oral option for convenience
Common Side Effects (often mild and improve over time):
⚠️ Nausea, vomiting, diarrhea, constipation
⚠️ Monitor for dehydration or low blood sugar; rare risks include pancreatitis or thyroid issues
At Diiaplus Clinic in Bengaluru, our endocrinology experts personalize semaglutide therapy for safe, effective results. Book a consultation today! 📞 DM or call 8317384316.